Restorbio Inc (NASDAQ:TORC) Stock Is Shorted More

June 12, 2018 - By Maria Brooks

The stock of Restorbio Inc (NASDAQ:TORC) registered an increase of 16.98% in short interest. TORC’s total short interest was 919,600 shares in June as published by FINRA. Its up 16.98% from 786,100 shares, reported previously. With 107,900 shares average volume, it will take short sellers 9 days to cover their TORC’s short positions.

The stock increased 0.59% or $0.06 during the last trading session, reaching $10.2. About 133,670 shares traded. resTORbio, Inc. (NASDAQ:TORC) has 0.00% since June 12, 2017 and is . It has underperformed by 12.57% the S&P500.

resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. The company has market cap of $286.07 million. The Company’s lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. It currently has negative earnings. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system.

More news for resTORbio, Inc. (NASDAQ:TORC) were recently published by:, which released: “resTORbio Announces Appointment of Kerry Russell, MD, Ph.D., as Vice President of Clinical Development” on June 12, 2018.‘s article titled: “resTORbio to Host Key Opinion Leader Symposium on TORC1 Inhibition” and published on May 22, 2018 is yet another important article.

resTORbio, Inc. (NASDAQ:TORC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: